Skin cancer generates the most urgent referrals of any cancer in the UK and referrals are growing by over 11% year on year [1]. Despite sustained and considerable effort from dermatology departments, this has led to waitlists growing significantly – provisional NHS data suggests that at the end of 2022 11% of urgent skin cancer referrals are waiting more than 4 weeks for a first assessment, amounting to 17,454 patients in Q3 FY 22/23 .
Skin Analytics’ UKCA marked Class IIa AI as a Medical Device (AIaMD), DERM (Deep Ensemble for the Recognition of Malignancy), is built around our custom built teledermatology platform to help triage patients into the right place, at the right time and to conserve dermatologist capacity for patients who need it.
DERM has identified 3 out of every 4 benign lesions assessed, while finding 99% of cancers including 100% of melanoma and squamous cell carcinoma [2], allowing dermatologists to focus on the patients that need them most.
Skin Analytics and the NHS launched the world’s first AI skin cancer pathway in 2020 as well as the first patient autonomously assessed by AI
Our latest quarterly report showed
DERM identified
Skin Analytics has helped Secondary Care organisations to remove the need for
Skin Analytics has deployed 12 NHS partners across primary and secondary care
If you would like to know more about how Skin Analytics can help you and your dermatology team deliver best in class dermatology, get in touch.
